Ash Biomedical’s Managing Director, Ade Shodeinde, authored a widely read op-ed published on LinkedIn Pulse responding to the national conversation around GlaxoSmithKline’s exit from Nigeria.
The article argued that the departure of multinationals represents an opportunity — not a setback — for homegrown manufacturers like Ash Biomedical, who are already building the infrastructure for end-to-end IVD production. The piece referenced global initiatives by the Global Fund, PEPFAR, and Unitaid to localise health manufacturing in Africa, positioning Ash Biomedical as a company built for this moment.